231 related articles for article (PubMed ID: 22593237)
1. Analysis of variola and vaccinia virus neutralization assays for smallpox vaccines.
Hughes CM; Newman FK; Davidson WB; Olson VA; Smith SK; Holman RC; Yan L; Frey SE; Belshe RB; Karem KL; Damon IK
Clin Vaccine Immunol; 2012 Jul; 19(7):1116-8. PubMed ID: 22593237
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of smallpox vaccines using variola neutralization.
Damon IK; Davidson WB; Hughes CM; Olson VA; Smith SK; Holman RC; Frey SE; Newman F; Belshe RB; Yan L; Karem K
J Gen Virol; 2009 Aug; 90(Pt 8):1962-1966. PubMed ID: 19339477
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of LC16m8, an attenuated smallpox vaccine in vaccinia-naive adults.
Kennedy JS; Gurwith M; Dekker CL; Frey SE; Edwards KM; Kenner J; Lock M; Empig C; Morikawa S; Saijo M; Yokote H; Karem K; Damon I; Perlroth M; Greenberg RN
J Infect Dis; 2011 Nov; 204(9):1395-402. PubMed ID: 21921208
[TBL] [Abstract][Full Text] [Related]
4. Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox.
Pittman PR; Hahn M; Lee HS; Koca C; Samy N; Schmidt D; Hornung J; Weidenthaler H; Heery CR; Meyer TPH; Silbernagl G; Maclennan J; Chaplin P
N Engl J Med; 2019 Nov; 381(20):1897-1908. PubMed ID: 31722150
[TBL] [Abstract][Full Text] [Related]
5. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.
Meseda CA; Garcia AD; Kumar A; Mayer AE; Manischewitz J; King LR; Golding H; Merchlinsky M; Weir JP
Virology; 2005 Sep; 339(2):164-75. PubMed ID: 15993917
[TBL] [Abstract][Full Text] [Related]
6. Major neutralizing sites on vaccinia virus glycoprotein B5 are exposed differently on variola virus ortholog B6.
Aldaz-Carroll L; Xiao Y; Whitbeck JC; de Leon MP; Lou H; Kim M; Yu J; Reinherz EL; Isaacs SN; Eisenberg RJ; Cohen GH
J Virol; 2007 Aug; 81(15):8131-9. PubMed ID: 17522205
[TBL] [Abstract][Full Text] [Related]
7. Antibody profiling by proteome microarray reveals the immunogenicity of the attenuated smallpox vaccine modified vaccinia virus ankara is comparable to that of Dryvax.
Davies DH; Wyatt LS; Newman FK; Earl PL; Chun S; Hernandez JE; Molina DM; Hirst S; Moss B; Frey SE; Felgner PL
J Virol; 2008 Jan; 82(2):652-63. PubMed ID: 17977963
[TBL] [Abstract][Full Text] [Related]
8. Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus.
Earl PL; Americo JL; Wyatt LS; Espenshade O; Bassler J; Gong K; Lin S; Peters E; Rhodes L; Spano YE; Silvera PM; Moss B
Proc Natl Acad Sci U S A; 2008 Aug; 105(31):10889-94. PubMed ID: 18678911
[TBL] [Abstract][Full Text] [Related]
9. A novel high-throughput vaccinia virus neutralization assay and preexisting immunity in populations from different geographic regions in China.
Liu Q; Huang W; Nie J; Zhu R; Gao D; Song A; Meng S; Xu X; Wang Y
PLoS One; 2012; 7(3):e33392. PubMed ID: 22438922
[TBL] [Abstract][Full Text] [Related]
10. Bioterrorism. Smallpox vaccinations: how much protection remains?
Cohen J
Science; 2001 Nov; 294(5544):985. PubMed ID: 11691969
[No Abstract] [Full Text] [Related]
11. The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection.
Coulibaly S; Brühl P; Mayrhofer J; Schmid K; Gerencer M; Falkner FG
Virology; 2005 Oct; 341(1):91-101. PubMed ID: 16061267
[TBL] [Abstract][Full Text] [Related]
12. [Development of a numerically additive combined vaccine against tetanus and smallpox].
Mayr A; Baljer G; Wagner C; Sailer J
Zentralbl Bakteriol Mikrobiol Hyg A; 1985 Apr; 259(2):206-18. PubMed ID: 2990123
[TBL] [Abstract][Full Text] [Related]
13. Smallpox vaccines: targets of protective immunity.
Moss B
Immunol Rev; 2011 Jan; 239(1):8-26. PubMed ID: 21198662
[TBL] [Abstract][Full Text] [Related]
14. MVA: a cuckoo in the vaccine nest?
Stittelaar KJ; Osterhaus AD
Vaccine; 2001 Jun; 19(27):V-VI. PubMed ID: 11395217
[No Abstract] [Full Text] [Related]
15. Antibodies to the A27 protein of vaccinia virus neutralize and protect against infection but represent a minor component of Dryvax vaccine--induced immunity.
He Y; Manischewitz J; Meseda CA; Merchlinsky M; Vassell RA; Sirota L; Berkower I; Golding H; Weiss CD
J Infect Dis; 2007 Oct; 196(7):1026-32. PubMed ID: 17763325
[TBL] [Abstract][Full Text] [Related]
16. Development of smallpox vaccine candidates with integrated interleukin-15 that demonstrate superior immunogenicity, efficacy, and safety in mice.
Perera LP; Waldmann TA; Mosca JD; Baldwin N; Berzofsky JA; Oh S
J Virol; 2007 Aug; 81(16):8774-83. PubMed ID: 17553867
[TBL] [Abstract][Full Text] [Related]
17. Third-generation smallpox vaccines: challenges in the absence of clinical smallpox.
Meseda CA; Weir JP
Future Microbiol; 2010 Sep; 5(9):1367-82. PubMed ID: 20860482
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and protection efficacy of subunit-based smallpox vaccines using variola major antigens.
Sakhatskyy P; Wang S; Zhang C; Chou TH; Kishko M; Lu S
Virology; 2008 Feb; 371(1):98-107. PubMed ID: 17950773
[TBL] [Abstract][Full Text] [Related]
19. Statistical approach to estimate vaccinia-specific neutralizing antibody titers using a high-throughput assay.
Kennedy R; Pankratz VS; Swanson E; Watson D; Golding H; Poland GA
Clin Vaccine Immunol; 2009 Aug; 16(8):1105-12. PubMed ID: 19535540
[TBL] [Abstract][Full Text] [Related]
20. Effect of vaccination with modified vaccinia Ankara (ACAM3000) on subsequent challenge with Dryvax.
Seaman MS; Wilck MB; Baden LR; Walsh SR; Grandpre LE; Devoy C; Giri A; Noble LC; Kleinjan JA; Stevenson KE; Kim HT; Dolin R
J Infect Dis; 2010 May; 201(9):1353-60. PubMed ID: 20350190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
